CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 150 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02489773
NCT02489773N/ACompleted

Lucica ® Glycated Albumin-L Clinical Program - Pivotal Study

Asahi Kasei Therapeutics Corporation·observational·Posted Jul 3, 2015·Updated Nov 21, 2019

In Brief

An observational study for Diabetes. Completed, enrolled 150 participants across 8 sites.

Detailed Summary

To confirm that Lucica ® Glycated Albumin-L is useful for the intermediate term (preceding 2-3 weeks) monitoring of glycemic control in patients with diabetes.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 3, 2015
Enrollment StartJun 1, 2015
Primary CompletionJul 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 11.0 years ago